NASDAQ: ACETAdicet Bio Inc Stock
$9.00+0.38 (+4.41%)
Updated Jul 2, 2026
ACET Price
$9.00
Fair Value Price
$3.51
Market Cap
$84.13M
52 Week Low
$6.01
52 Week High
$17.44
P/E
-0.65x
P/B
0.6x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$108.83M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$91M
Beta
1.36
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ACET Overview
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACET's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ACET
Ranked#136 of 463
Ranked#136 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important ACET news, forecast changes, insider trades & much more!
ACET News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACET scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACET ($9.00) is overvalued by 156.5% relative to our estimate of its Fair Value price of $3.51 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ACET ($9.00) is not significantly undervalued (156.5%) relative to our estimate of its Fair Value price of $3.51 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACET is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACET due diligence checks available for Premium users.
Valuation
ACET fair value
Fair Value of ACET stock based on Discounted Cash Flow (DCF)
Price
$9.00
Fair Value
$3.51
Overvalued by
156.50%
ACET ($9.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACET ($9.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACET is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACET price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.65x
Industry
17.59x
Market
8.54x
ACET price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.6x
Industry
5.6x
ACET is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACET's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.2M
Profit Margin
0%
ACET's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$169.4M
Liabilities
$29.3M
Debt to equity
0.21
ACET's short-term assets ($140.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACET's short-term assets ($140.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACET's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACET's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.5M
Investing
$18.9M
Financing
-$65.0k
ACET's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACET vs Biotech Stocks
Adicet Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.